Tibet Aim Pharm

Tibet Aim Pharm EBITDA per Employee

The EBITDA per Employee of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 220,571.10 CNY. In the previous year, EBITDA per Employee was 156,194.77 CNY — a change of 41.22% (higher).

EBITDA per Employee

220,571.10CNY

YoY

41.22%

Last updated:

EBITDA per Employee of Tibet Aim Pharm is 2025 220,571.10 CNY. EBITDA per Employee of Tibet Aim Pharm was 2024 156,194.77 CNY. It decreases by 41.22% higher compared to the previous year.

The Tibet Aim Pharm EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
71,714.78 CNY
Jan 1, 2019
120,142.40 CNY
Jan 1, 2020
112,586.94 CNY
Jan 1, 2021
138,233.94 CNY
Jan 1, 2022
149,039.74 CNY
Jan 1, 2023
74,849.93 CNY
Jan 1, 2024
156,194.77 CNY
Jan 1, 2025
220,571.10 CNY
The Tibet Aim Pharm EBITDA per Employee history
YEAREBITDA per EmployeeYoY
220,571.10CNY+41.22%
156,194.77CNY+108.68%
74,849.93CNY-49.78%
149,039.74CNY+7.82%
138,233.94CNY+22.78%
112,586.94CNY-6.29%
120,142.40CNY+67.53%
71,714.78CNY-53.20%
153,246.32CNY+36.05%
112,642.35CNY+5.43%
106,841.47CNY+48.48%
71,957.67CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

EBITDA per Employee of Tibet Aim Pharm is 220,571.10 CNY in 2025.

EBITDA per Employee of Tibet Aim Pharm changed from 156,194.77 CNY to 220,571.10 CNY, representing a 41.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Tibet Aim Pharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm